BOSTON, Mass. ( TheStreet) -- A calendar of important, potentially stock-moving biotech events for May:

May 1-6

Digestive Disease Week annual meeting.

May 3-6

BIO International Convention.

May 3-7

Amylin Pharmaceuticals ( AMLN), Eli Lilly ( LLY) and Alkermes ( ALKS) expected to hear back from FDA on new approval decision date for the diabetes drug Bydureon. Class 1 response means June date; Class 2 response means October date.

Biotech Busts and Breakthroughs (Forbes)

May 4

FDA approval decision date for InterMune's ( ITMN) Esbriet (pirfenidone) for treatment of idiopathic pulmonary fibrosis.

Cleveland BioLabs ( CBLI) analyst/investor meeting.

Vanda Pharmaceuticals ( VNDA - Get Report) first-quarter earnings, including update on commercial launch of the schizophrenia drug Fanapt.

May 5

Allos Therapeutics ( ALTH) first-quarter earnings, including update on commercial launch of the lymphoma drug Folotyn.

King Pharmaceuticals ( KG) first quarter earnings: Will King update investors on its pain drug partnership with Acura Pharmaceuticals ( ACUR)?

May 6

Genzyme ( GENZ) analyst/investors meeting.

FDA advisory panel to review Questcor Pharmaceuticals' ( QCOR) Acthar for infantile spasms. The FDA's briefing documents should be posted to the agency's web site on May 4 or May 5.

Sequenom ( SQNM) first-quarter earnings.

May 7

Mike Huckman's last day at CNBC. Good luck, Mike!

Cytori Therapeutics ( CYTX - Get Report) reports full, six-month results from Apollo trial (heart attack) and preliminary, six-month results from Precise (chronic ischemia) trial at Stem Cell Therapy and Cardiovascular Innovation conference.

May 11

Merck ( MRK) analyst/investor meeting.

May 14

Athersys ( ATHX) investor/analyst meeting.

Cell Therapeutics ( CTIC) rescheduled shareholder meeting.

Patent expiration for Taxotere, marketed by Sanofi-Aventis ( SNY).

May 14-19

American Pain Society annual meeting.

May 14-19

American Thoracic Society annual meeting.

May 15-19

American College of Obstetricians and Gynecologists annual meeting.

May 19-23

American Society of Gene and Cell Therapy

May 22-27

American Psychiatric Association annual meeting.

May 29 - June 3

American Urological Association annual meeting: The medical meeting debut of Dendreon's ( DNDN) Provenge as a fully approved prostate cancer immunotherapy!

-- Reported by Adam Feuerstein in Boston.

Follow Adam Feuerstein on Twitter.

Adam Feuerstein writes regularly for TheStreet.com. In keeping with TSC's editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet.com. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.